The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The partial µ-opioid agonist buprenorphine in autism spectrum disorder: a case report ; volume:16 ; number:1 ; day:15 ; month:4 ; year:2022 ; pages:1-6 ; date:12.2022
Journal of medical case reports ; 16, Heft 1 (15.4.2022), 1-6, 12.2022
- Creator
-
Skoglund, Charlotte
Leknes, Siri
Heilig, Markus
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13256-022-03384-w
- URN
-
urn:nbn:de:101:1-2022062722055709720854
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Skoglund, Charlotte
- Leknes, Siri
- Heilig, Markus
- SpringerLink (Online service)
Other Objects (12)
![The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Better agonist for the opioid receptors
Alcohol use in opioid agonist treatment
Interim opioid agonist treatment for opioid addiction: a systematic review
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Better agonist for the opioid receptors
Alcohol use in opioid agonist treatment
Interim opioid agonist treatment for opioid addiction: a systematic review
The partial μ-opioid [My-opioid] receptor agonist buprenorphine inhibits voltage gated Na+ channels in a local anesthetic like manner
Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
Buprenorphine deaths confirmed by toxicology reveal a low proportion of opioid agonist treatment before death in Finland
Successful buprenorphine transition while overlapping with a full opioid agonist to treat chronic pain: a case report
Single high-dose buprenorphine for opioid craving during withdrawal
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study
Prolonged-release opioid agonist therapy: qualitative study exploring patients’ views of 1-week, 1-month, and 6-month buprenorphine formulations
Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder
Better agonist for the opioid receptors
Alcohol use in opioid agonist treatment